imi outputs - november 2015
TRANSCRIPT
What is €5 billion worth?
Magda Gunn, IMI Scientific Project Manager
Drug discovery is complex
Focus on unmet needs
Non-competitive collaborative
research
Competitive Calls for proposals
Open collaboration in public-private
consortia
Data sharing, dissemination
of results…
Industry contribution is in kind
A partnership between EU
Commission and the European
Federation of Pharmaceutical
Industries and Association
(EFPIA)
Key concepts
Typical IMI project
Industry
ACADEMIA
HOSPITALS
PATIENTS’
ORGANISATIONS
SMALL AND
MEDIUM-SIZED
ENTERPRISES
REGULATORS
Pharma
1
Pharma 2
Pharma
3
Pharma
4
Pharma 5
Pharma
6
Private
Investment
in kind
EU Public
Funding
cash
Many stakeholders many expectations
2.7 billion REMAINING
17 CALLS FOR PROPOSALS
2.6 billion
COMMITTED
68 PROJECTS
0% 5% 10% 15% 20% 25% 30% 35% 40%
Relative Effectiveness
Drug kinetics
Drug delivery
Sustainable chemistry
Lung diseases
Education and Training
Vaccines
Geriatrics
Biologicals
Inflamatory disorders
Cancer
Data Management
Stem cells
Drug safety
Metabolic disorders
Brain disorders
Drug Discovery
Infectious diseases
Performance monitoring framework
Scientific output
Impact on drug development
Impact on regulatory framework
Business opportunities and sustainability
Socio-economic impact
Information, communication and dissemination
Scientific Output
2010 2011 2012 2013 2014
1134 publications by Dec 2014
427 376 224
24%
HIGHLY CITED
1134 PUBLICATIONS
2.19
CITATION IMPACT
9359 CITATIONS
IMI scientific output
Benchmarking
0 0.5 1 1.5 2 2.5
ICMR
World
EU-28
C-Path
CSIRO
GCGH
WT
MRC
FNIH
IMI
Citation impact IMI vs. comparators
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Genetics & Heredity
Psychiatry
Clinical Neurology
Neurosciences
Rheumatology
Biochemistry & Molecular…
Immunology
Pharmacology & Pharmacy
Toxicology
Endocrinology & Metabolism
IMI vs. EU in various research fields
IMI papers EU papers
Collaboration delivers excellence
INTERNATIONAL collaboration
50%
of IMI publications
Collaboration BETWEEN
SECTORS 61% of IMI publications
collaboration BETWEEN INSTITUTIONS
75% of IMI publications
0
1
2
3
Cross-institution Cross-sector International
Citation impact
Collaborative Non-collaborative
Data & analysis: Thomson Reuters (Custom Analytics & Engineered Solutions)
Tracking collaborations across EU Co-authorship between IMI-supported researchers Calls 1-4
Pre IMI funding award Post IMI funding award
Data & analysis: Thomson Reuters (Custom Analytics & Engineered Solutions)
Securing regulatory relevance
Securing regulatory relevance
New standards and best
practices derived from IMI
projects
Number of scientific advice and
qualified opinions initiated by the
IMI projects at the EMA and FDA
Number of regulatory guidelines
derived from IMI projects
Business development and sustainability
IMI project patenting trends 20 patent applications
3.2 patents per €10 million of costs accepted by IMI
Business relevant outputs (n=50)
New Projects
Companies & joint ventures
Foundations & non-profits
Spin-offs breakdown
Job creation as a result of IMI projects
2 272 direct jobs created
13 000 indirect jobs*
* https://researchcouncil.files.wordpress.com/2013/08/walifescienceseconimpactstudy.pdf
Key stakeholder involvement
SMEs receive 18% of IMI funding
15% of IMI participants are SMEs
Promoting SME participation
Thanks to IMI the company went from 6 to 50 employees.
Now they are ready to further expand.
“1st product released to the market in 2013 – IMI was instrumental in
validation of the first cell line product, 2nd product release planned this
year, 3rd diagnostic product in development.
In preparation: a new patent filing to protect technologies for the
creation of third generation human beta cell lines.
